Funakoshi A, Miyasaka K, Shinozaki H, Kitani K
Third Department of Internal Medicine, Kyushu University Faculty of Medicine, Fukuoka, Japan.
Gastroenterol Jpn. 1988 Oct;23(5):559-63. doi: 10.1007/BF02779489.
Exocrine pancreatic secretion to intravenous injections of a new stimulant of gastrointestinal motility, R51,619 (cisapride) was studied in conscious rats, and in the isolated pancreatic acini in vitro. The injection of cisapride (2 mg/kg) significantly increased fluid, bicarbonate and protein output in vivo. Atropine completely abolished the pancreatic responses to cisapride, and CR 1409, a new glutaramic acid derivative and a competitive cholecystokinin (CCK) inhibitor, tended to decrease the cisapride-induced pancreatic exocrine secretion. However, amylase release and Ca2+ efflux from the isolated pancreatic acini were not stimulated. These results suggest that cisapride indirectly affects the pancreatic exocrine secretion primarily by releasing acethycholine from the intrapancreatic nerve endings and in part by releasing CCK from the duodenum, but has no direct action on the pancreas.
在清醒大鼠体内以及体外分离的胰腺腺泡中,研究了静脉注射一种新的胃肠动力刺激剂R51,619(西沙必利)后外分泌性胰腺分泌的情况。注射西沙必利(2毫克/千克)可显著增加体内液体、碳酸氢盐和蛋白质的分泌量。阿托品完全消除了胰腺对西沙必利的反应,而一种新的谷氨酸衍生物CR 1409,作为一种竞争性胆囊收缩素(CCK)抑制剂,倾向于减少西沙必利诱导的胰腺外分泌。然而,分离的胰腺腺泡中的淀粉酶释放和钙离子外流并未受到刺激。这些结果表明,西沙必利主要通过从胰腺内神经末梢释放乙酰胆碱,部分通过从十二指肠释放CCK来间接影响胰腺外分泌,但对胰腺没有直接作用。